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At a children’s hospital in Riga, Latvia, isolates identified as Salmonella typhimurium were found to be
resistant to expanded-spectrum cephalosporins. Two of the resistant strains were analyzed for the mechanism
of cephalosporin resistance. Isoelectric focusing revealed a common b-lactamase with a pI of 8.8. In addition,
one of the strains produced a pI 7.6 b-lactamase. A transconjugant producing only the pI 7.6 enzyme was
susceptible to expanded-spectrum cephalosporins; therefore, this enzyme was most likely SHV-1. Transfor-
mants producing only the pI 8.8 b-lactamase were resistant to cefotaxime and aztreonam but were susceptible
or intermediate to ceftazidime. A substrate profile determined spectrophotometrically with purified enzyme
revealed potent activity against cefotaxime, with a relative kcat value of 95 (benzylpenicillin equal to 100). The
enzyme showed lower relative kcat values for ceftazidime (3.3) and aztreonam (9.3). In addition, the enzyme was
inhibited by clavulanate, sulbactam and tazobactam, with 50% inhibitory concentrations of 19, 100, and 3.4
nM, respectively. These results indicated the presence of an unusual extended-spectrum b-lactamase. The gene
expressing the pI 8.8 b-lactamase was cloned. Nucleotide sequencing revealed a b-lactamase gene that differs
from the gene encoding CTX-M-2, which also originated from S. typhimurium, by 11 nucleotides, 4 of which
result in amino acid substitutions: Ala27Thr, Val230Gly, Glu254Ala, and Ile278Val. These results indicated the
presence of a novel extended-spectrum b-lactamase, designated CTX-M-5, that specifically confers resistance
to cefotaxime.
Resistance to expanded-spectrum b-lactam antibiotics in the
Enterobacteriaceae is often due to the presence of extended-
spectrum b-lactamases (ESBLs), which are most often deriv-
atives of TEM or SHV enzymes (11, 17). However, there is a
small but growing family of plasmid-mediated ESBLs, includ-
ing CTX-M-1 (MEN-1) (2, 4, 5), CTX-M-2 (3, 5), CTX-M-3
(13), CTX-M-4 (12), Toho-1 (15), and Toho-2 (18), that pref-
erentially hydrolyze cefotaxime. These enzymes are not closely
related to TEM or SHV b-lactamases (5) but are all members
of Ambler’s class A. ESBLs have been found previously in
strains of Salmonella spp. including Salmonella typhimurium
strains from Turkey (29), Argentina (3, 26), Tunisia (6), Spain
(20), and Russia (12). Two of these reports described the
CTX-M-2 and the CTX-M-4 b-lactamases (3, 12).
A large outbreak of gastroenteritis caused by Salmonella sp.
has occurred among children in Latvia. Over 4,000 cases were
reported from 1991 through the first quarter of 1998. Approx-
imately 70% of these patients were under 1 year old, and the
illnesses were moderate to severe, with bloody stools and high
fever. Some of the cases were complicated by extraintestinal
infections. The epidemiology of this outbreak is currently un-
der investigation. In addition to the hospitalized patients, some
of the cases occurred among babies residing in orphanages.
The clinical isolates of S. typhimurium associated with the
majority of these infections were particularly noteworthy be-
cause of their increased resistance to expanded-spectrum
b-lactam antibiotics, especially cefotaxime. In this study, we
report a new member of the CTX-M cefotaxime-hydrolyzing
b-lactamase family, designated CTX-M-5.
(This work was presented in part at the 37th Interscience
Conference on Antimicrobial Agents and Chemotherapy, To-
ronto, Ontario, Canada, 28 September to 1 October 1997 [10].)
MATERIALS AND METHODS
Bacterial strains. Bacterial strains used in this study are listed in Table 1. S.
typhimurium strains were cefotaxime-resistant clinical isolates obtained from
individual patients at Children’s Hospital, Riga, Latvia. Escherichia coli DH5a
and E. coli DH5a/pCLL2300 were used in transformation, transconjugation, and
cloning experiments.
Identification and susceptibility tests. The isolates were identified initially as
S. typhimurium in the microbiology laboratory of the Children’s Hospital Medical
Academy of Latvia. This identification was confirmed in the reference laboratory
by the API-20E identification system (bioMérieux-Vitek, Hazelwood, Mo.).
MICs of various b-lactam antibiotics were determined with broth microdilution
tests by standard methods (21). The following antibiotics were used: piperacillin
and tazobactam (Lederle Laboratories, Pearl River, N.Y.); ticarcillin and potas-
sium clavulanate (Beecham Laboratories, Bristol, Tenn.); sulbactam (Pfizer Inc.,
New York, N.Y.); ceftazidime (Glaxo Group Research Ltd., Greenford, En-
gland); cefotaxime (Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.);
imipenem (Merck, Rahway, N.J.); aztreonam, cefepime, and benzylpenicillin
(Bristol-Myers Squibb, Princeton, N.J.); cephaloridine (Eli Lilly, Indianapolis,
Ind.); cefotetan (Zeneca Pharmaceuticals, Wilmington, Del.); and cefoxitin (Sig-
ma Chemical Company, St. Louis, Mo.). Conditions used for testing b-lactam–
b-lactamase inhibitor combinations were those recommended by the National
Committee for Clinical Laboratory Standards (NCCLS) (21): ampicillin-sulbac-
tam, 2:1 ratio of drug to inhibitor; ticarcillin-clavulanate, constant concentration
of 2 mg/ml of inhibitor; piperacillin-tazobactam, constant concentration of 4
mg/ml of inhibitor. Susceptibility to non-b-lactam antibiotics was determined by
a disk diffusion assay (22).
IEF and b-lactamase assays. Crude preparations of b-lactamases from clinical
isolates were obtained by repeated freezing-thawing in 0.02 M sodium acetate,
pH 5.2. Isoelectric focusing (IEF) was performed by the method of Matthew et
al. (19) by using an LKB Multiphor apparatus with prepared PAGplates, pH 3.5
to 9.5 (Pharmacia LKB, Piscataway, N.J.). The isoelectric point (pI) of each
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enzyme was confirmed by activity staining with nitrocefin (Becton Dickinson
Microbiology Systems, Cockeysville, Md.) following IEF. The pI of CTX-M-5
was calculated by using b-lactamase standards with known isoelectric points.
E. coli DH5a/pCLL3417, which produces the pI 8.8 CTX-M-5 b-lactamase
from cefotaxime-resistant S. typhimurium, was used for further enzymatic anal-
ysis. CTX-M-5 b-lactamase crude extracts were obtained from 2 liters of log-
phase cells in Trypticase soy broth after five cycles of freezing-thawing in 0.02 M
sodium acetate followed by 30 min of ultracentrifugation at 100,000 3 g using a
Beckman L8-M ultracentrifuge. This enzyme extraction was initially eluted from
a Sephadex G-75 column equilibrated with 50 mM phosphate buffer, pH 7.0.
Fractions were monitored at 280 nm for protein and tested for b-lactamase
hydrolytic activity with 50 mg of nitrocefin per ml. Fractions with high enzymatic
activity were pooled, concentrated, and subjected to a QAE A50 anion-exchange
column equilibrated with 20 mM TES [N-tris(hydroxymethyl)methyl-2-aminoeth-
anesulfonic acid] buffer, pH 8.3. Eluents with enzyme activity were then pooled
and concentrated. The purity of the enzyme was checked by using sodium
dodecyl sulfate (SDS)–12% polyacrylamide gel electrophoresis (PAGE), as de-
scribed previously (9).
The enzyme hydrolysis rates of purified CTX-M-5 were determined in 50 mM
PO4, pH 7.0, with a Beckman DU7400 spectrophotometer. For each substrate,
the initial velocities were determined at six to eight substrate concentrations. The
kinetic parameters kcat and Km were expressed as means of at least two inde-
pendent kinetic evaluations and were calculated by the computer program
ENZPACK (Biosoft; Elsevier). The standard deviation of each parameter was
less than 20%. For the inhibition study, enzyme and inhibitor were preincubated
in a volume of 50 ml for 10 min at 25°C before the addition of 50 mg of nitrocefin
per ml (final volume, 1,000 ml). Initial rates of hydrolysis were monitored spec-
trophotometrically at 495 nm, and 50% inhibitory concentrations (IC50s) were
determined graphically.
Nucleic acid techniques. DNA isolation, restriction enzyme digestions, recom-
binant DNA manipulations, and transformations of plasmid DNA were per-
formed as described by Sambrook et al. (27). Plasmids conferring ampicillin
resistance were transferred from the clinical isolates to an ampicillin-susceptible,
kanamycin-resistant E. coli host, strain DH5a/pCLL2300, by filter mating (28).
Transconjugants were selected on Luria-Bertani agar plates containing 100 mg of
ampicillin per ml and 30 mg of kanamycin per ml. Plasmids conferring cefotaxime
resistance were transformed into E. coli DH5a by using CaCl2 (27). SHV-1
b-lactamase was detected by PCR and subsequent NheI digestion, as described
previously (23).
To facilitate nucleotide sequencing, a 7-kb BamHI fragment encoding the
b-lactamase with a pI of 8.8 from S. typhimurium 34 was cloned from an alkaline
lysis plasmid DNA preparation into pCLL2300, a kanamycin resistance-confer-
ring cloning vector (24), and the resulting plasmid was designated pCLL3417.
Because the pI 8.8 b-lactamase present in these strains appeared to be pheno-
typically similar to the CTX-M-1 and CTX-M-2 b-lactamases, sequencing was
initiated with 17-bp forward (59-TCTGACGCTGGGTAAAG-39) and reverse
(59-CTTTACCCAGCGTCAGA-39) primers derived from a consensus region of
the sequences of these two b-lactamase genes (5). Subsequently, both strands of
the entire b-lactamase gene were sequenced with a nested set of custom-synthe-
sized oligonucleotide primers which were specific for the CTX-M-5 b-lactamase
gene. Initial DNA sequencing was performed on double-stranded plasmid DNA
with a Sequenase kit (United States Biochemical, Cleveland, Ohio) with 35S-
dATP label (Amersham, Arlington Heights, Ill.) and completed by dideoxy
sequencing with a Taq dye terminator kit (Applied Biosystems, Inc., Foster City,
Calif.), according to the respective manufacturers’ instructions.
Nucleotide sequence accession number. The nucleotide sequence data for
blaCTX-M-5 was submitted to the GenBank nucleotide sequence database and
assigned accession no. U95364.
RESULTS
Characterization of clinical isolates. The pIs of the b-lacta-
mases present in crude extracts obtained from the clinical
isolates are shown in Table 1. The clinical isolates expressed a
b-lactamase with a pI of approximately 8.8. In addition, strain
34 produced a second enzyme with a pI of 7.6, which correlated
with SHV-1. The presence of a non-ESBL SHV-type (most
likely SHV-1) enzyme in the clinical isolates was confirmed in
this strain by PCR with SHV-1 specific oligonucleotides and
subsequent digestion with NheI (data not shown).
Plasmid profiles of strains 28 and 34 revealed multiple small
plasmids ranging in size from 2 to 10 kb. In addition, strain 34
had one large plasmid (.50 kb). Mating experiments trans-
ferred the single large plasmid from S. typhimurium 34. This
transconjugant (DH5a/pCLL3422 1 pCLL2300) expressed
only the pI 7.6 b-lactamase. Transforming plasmid DNA from
strain 34 resulted in transformant DH5a/pCLL3425, which
contained a single 10-kb plasmid and expressed only the pI 8.8
b-lactamase.
Susceptibility. MICs for the clinical isolates, transformant,
transconjugant, and clone are listed in Table 2. With NCCLS
criteria for intermediate and resistant used to define clinical
resistance, the clinical isolates of S. typhimurium were resistant
to the penicillins, amoxicillin-clavulanate, ampicillin-sulbac-
tam, ticarcillin-clavulanate, cefotaxime, and aztreonam. The
clinical isolates were susceptible to imipenem, cefoxitin, and
ceftazidime, although the MICs of the latter were increased. S.
typhimurium 28, which lacks the pI 7.6 b-lactamase, was sus-
ceptible to piperacillin-tazobactam. In addition, the clinical
isolates of S. typhimurium were also resistant to chloramphen-
icol and trimethoprim-sulfamethoxazole but were susceptible
to gentamicin, kanamycin, and ciprofloxacin (data not shown).
The pI 7.6 b-lactamase plasmid present in transconjugant
strain DH5a/pCLL3422 1 pCLL2300 conferred resistance to
the penicillins, amoxicillin-clavulanate, ampicillin-sulbactam,
and ticarcillin-clavulanate. The pI 8.8 b-lactamase in strains
DH5a/pCLL3425 and DH5a/pCLL3417 conferred resistance
to cefotaxime and aztreonam, the penicillins, and the b-lacta-
mase inhibitor combinations except for piperacillin-tazobac-
tam. Although MICs of ceftazidime were increased, they were
not increased to the level that would be considered resistant
clinically (21).
b-Lactamase characterization. After two steps of column
chromatography, the purified CTX-M-5 enzyme yielded a ma-
jor single band (95% homogeneity) in both IEF and SDS–12%
PAGE. From SDS-PAGE, the molecular weight of the CTX-
M-5 b-lactamase was estimated to be 29,000 based upon Bio-
Rad low-molecular-weight markers. The isoelectric point of
TABLE 1. Bacterial strains used in this study




28 S. typhimurium pCLL3425 Clinical isolate 8.8 This study
34 S. typhimurium pCLL3422 1 pCLL3425 Clinical isolate 7.6, 8.8 This study
DH5a E. coli E. coli K-12 cloning strain None 14
F f80dlacZDM15 D(lacZYA-argF) U169 recAI
endAI hsdR17 (rK2 mK1) supE44 thiI gyrI relAI
DH5a E. coli pCLL2300 Kmr cloning vector None 24
DH5a E. coli pCLL3422 1 pCLL2300 Transconjugant of S. typhimurium 34 7.6 This study
DH5a E. coli pCLL3425 Transformant of S. typhimurium 34 8.8 This study
DH5a E. coli pCLL3417 7-kb BamHI fragment containing blaCTX-M-5 in
pCLL2300
8.8 This study












































homogeneously purified CTX-M-5 was 8.8, consistent with the
enzyme produced from the wild-type strain.
The substrate and inhibition profiles are shown in Table 3.
CTX-M-5 b-lactamase showed broad-spectrum hydrolytic ac-
tivity against penicillin, cephalosporins, and aztreonam. Cefo-
taxime was a good substrate for CTX-M-5, with comparable
hydrolytic activity (kcat, 210 s
21) and affinity (Km, 77 mM) to
those of benzylpenicillin. Cephaloridine was also a good sub-
strate, with higher hydrolytic activity but lower affinity. Cefta-
zidime was readily hydrolyzed by the CTX-M-5 enzyme but
had a lower rate (,5%) and lower affinity (higher Km) than
those of cefotaxime or benzylpenicillin. The physiological ef-
ficiency (kcat/Km) of CTX-M-5 for ceftazidime was only 6%
of that of cefotaxime. Aztreonam was also hydrolyzed by CTX-
M-5 with a lower rate and lower affinity than cefotaxime. Ce-
foxitin and imipenem were poor substrates for CTX-M-5, with
relative hydrolysis rates of ,0.1% of that of benzylpenicillin.
Clavulanic acid, tazobactam, and sulbactam were all effective
b-lactamase inhibitors for the CTX-M-5 b-lactamase, with
IC50s of 19, 100, and 3.4 nM respectively. CTX-M-5 is a cefo-
taxime-hydrolyzing b-lactamase which is inhibited by clavu-
lanate and is therefore classified in functional group 2be.
Nucleotide sequencing. The nucleotide sequence of blaCTX-M-5
is given in Fig. 1, and the derived amino acid sequence is given
in Fig. 2. The blaCTX-M-5 b-lactamase gene is 879 bp long, and
the encoded protein consists of 293 amino acids. It is 63.2%
identical to the CTX-M-1 b-lactamase gene and 97.5% iden-
tical to the CTX-M-2 b-lactamase gene (5). There is similar
homology on the protein level. The nucleotide sequence of
blaCTX-M-5 differs from blaCTX-M-2 by 11 nucleotides, 4 of
which give rise to amino acid changes: threonine for alanine
27, glycine for valine 230, alanine for glutamate 254, and valine
for isoleucine 278.
DISCUSSION
A serious outbreak of S. typhimurium in Latvia was further
complicated by the fact that the outbreak strain was resistant to
multiple antibiotics, including ampicillin, chloramphenicol, tri-
methoprim-sulfamethoxazole, and cefotaxime, which are com-
monly used to treat serious infections caused by Salmonella
spp. These strains were uniformly susceptible to ciprofloxacin;
however, the extremely young ages of most of the patients
prevented its use in treatment.
The isolates described in this report were resistant to cefo-
TABLE 2. MICs of b-lactam drugs for S. typhimurium clinical isolates and E. coli derivatives
Strain
MIC (mg/ml)a
AMP AMC SAM TIC TIM PIP PTZ CAZ CTX ATM IPM FOX
S. typhimurium strains
28 .128 16 64 .128 128 .128 2 8 128 32 0.25 2
34 .128 32 64 .128 .128 .128 64 8 128 32 0.25 2
E. coli strains
DH5a 8 8 8 4 1 1 0.25 0.25 #0.12 #0.12 0.25 8
DH5a/pCLL2300 8 8 8 4 1 1 0.25 0.25 #0.12 #0.12 0.25 8
DH5a/pCLL3422
1 pCLL2300
.128 64 32 .128 128 128 8 1 0.5 0.5 0.5 8
DH5a/pCLL3425 .128 32 32 .128 128 .128 1 16 .128 128 0.5 16
DH5a/pCLL3417 .128 32 64 .128 128 .128 0.5 16 .128 128 0.5 8
a MICs were determined in broth microdilution tests (21). AMP, ampicillin; AMC, amoxicillin-clavulanate; SAM, ampicillin-sulbactam; TIC, ticarcillin; TIM,
ticarcillin-clavulanate; PIP, piperacillin; PTZ, piperacillin-tazobactam; CAZ, ceftazidime; CTX, cefotaxime; ATM, aztreonam; IPM, imipenem; FOX, cefoxitin.















Benzylpenicillin 230 100 50 4,600
Cephaloridine 1,500 680 350 4,400
Cefotaxime 210 95 77 2,800
Ceftazidime 7.4 3.3 440 17
Aztreonam 21 9.3 730 29
Cefoxitin 0.41 0.18 NCa NC





a NC, not calculated (rates were too low to obtain reliable values).
FIG. 1. Nucleotide sequence of the blaCTX-M-5 b-lactamase gene. Under-
lined nucleotides are start and stop codons.












































taxime due to the presence of a novel extended-spectrum b-
lactamase, CTX-M-5. It is interesting that in this small family
of cefotaxime-hydrolyzing b-lactamase, CTX-M-2, which is
the enzyme most closely related to CTX-M-5, and CTX-M-4
also originated in S. typhimurium (3, 12). The strains of S.
typhimurium described by Bauernfeind et al. from which CTX-
M-2 was detected were isolated from an outbreak of severe
infections in Buenos Aires, Argentina, in 1990 (3). Therefore,
it is unlikely that the Argentinean strains are related to the
Latvian strains described in this study. Further observations of
E. coli, Klebsiella pneumoniae, and Proteus mirabilis strains
expressing CTX-M-2 were made in Germany, Israel, and Par-
aguay (5). The other members of the CTX-M family of b-lac-
tamases were found in E. coli and Citrobacter freundii strains
isolated in Germany, Italy, Japan, Poland, and Russia (2, 4, 12,
13, 15). The wide geographical distribution of occurrences of
these b-lactamases implies that they represent independent
genetic events; however, it is interesting that CTX-M-3, CTX-
M-4, and CTX-M-5 were all found in isolates from Eastern
European countries (12, 13). To date, all of the strains express-
ing CTX-M-type enzymes have carried the b-lactamase on a
plasmid. The origin of the enzymes remains unknown, al-
though they are most closely related to the chromosomally
mediated b-lactamase from Klebsiella oxytoca (5, 25).
The CTX-M family of ESBLs is interesting in that it has
uniquely potent hydrolytic activity against cefotaxime. Like the
cefotaxime hydrolyzing b-lactamases CTX-M-1, CTX-M-2,
and Toho-1 (3, 4, 15), CTX-M-5 has more potent activity
against cefotaxime than against ceftazidime. This finding con-
firms the analysis of the relationship between compound struc-
ture and enzymatic stability by Bauerfeind et al., who con-
cluded that the carboxy-isopropoximino group of ceftazidime
protects the compound from attack by the CTX-M-type en-
zymes, whereas the methoximino group of cefotaxime provides
the compound better affinity to the enzyme (4). The enzyme
kinetic data for CTX-M-2 (3), which is most closely related to
CTX-M-5, indicated a hydrolytic pattern similar to that of
CTX-M-5, in that cephaloridine is a better substrate than ben-
zylpenicillin or cefotaxime. Toho-1 (15), which differs from
CTX-M-2 by only two amino acid residues, hydrolyzed ceph-
aloridine and cefotaxime much faster (10- to 16-fold) than
benzylpenicillin. These differences in substrate profiles might
also represent experimental differences between various inves-
tigators’ laboratories.
The combination of CTX-M-5 and SHV-1 in three of the
clinical isolates studied conferred resistance to piperacillin-
tazobactam. However, clinical isolates or laboratory constructs
producing only one of these enzymes were susceptible to this
b-lactam–b-lactamase inhibitor combination. It appears that
the combination of SHV-1 plus an ESBL can confer resistance
to piperacillin-tazobactam, whereas strains expressing the
ESBL alone are often susceptible (7, 8, 16, 30). The resistance
to piperacillin-tazobactam in these strains expressing multiple
b-lactamases is most likely attributable to the SHV-1 enzyme,
which is not inhibited as well by b-lactamase inhibitors as most
other class A enzymes (11).
The prevalence of this cefotaxime-hydrolyzing b-lactamase
among S. typhimurium strains in Latvia may be related to the
increased usage of expanded-spectrum cephalosporins in re-
cent years; however, it is difficult to assess whether or not this
resistance developed as a direct result of cephalosporin ther-
apy. With the recognition of the high prevalence of resistance,
efforts have been made to curtail antibiotic use in patients with
salmonellosis, and efforts to control the spread of S. typhi-
murium are under way. The detection of a new member of the
CTX-M family in Latvia raises important questions about
whether such enzymes arise de novo in multiple geographic
locations or, alternatively, are transmitted across national bor-
ders. The importance of these questions emphasizes the need
for global surveillance of antibiotic resistance so that appro-
priate control strategies can be designed and implemented.
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